|
01 Jul 2021 |
SELLAS Reports Promising Updated Clinical Data and Initial Immune Response Profiles from Ongoing Phase 1/2 Study of Galinpepimut-S (GPS) Combined with Keytruda for Treating WT1+ Advanced Ovarian Cancer
|
|
30 Jun 2021 |
Altimmune Announces Update on AdCOVID™ Phase 1 Clinical Trial
|
|
30 Jun 2021 |
Elicio Therapeutics Announces Initiation of Its Phase 1/2 Dose-Escalation Study of ELI-002 (AMPLIFY-201) in KRAS-Driven Cancers
|
|
29 Jun 2021 |
VBI Vaccines Announces Initial Positive Phase 1 Data for Its eVLP Vaccine Candidate Against COVID-19
|
|
29 Jun 2021 |
Vaxzevria induced immunity for at least one year following a single dose and strong immune responses following either a late second dose or a third dose
|
|
29 Jun 2021 |
First COVID-19 variant vaccine AZD2816 Phase II/III trial participants vaccinated
|
|
24 Jun 2021 |
Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
|
|
22 Jun 2021 |
Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine
|
|
20 Jun 2021 |
BioNTech Announces First Patient Dosed in Phase 2 Clinical Trial of mRNA-based BNT111 in Patients with Advanced Melanoma
|
|
17 Jun 2021 |
CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV
|
|
15 Jun 2021 |
COVID-19 Vaccine AstraZeneca effective against Delta (‘Indian’) variant
|
|
14 Jun 2021 |
Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
|
|
13 Jun 2021 |
Novavax Announces Positive Data from Three Complementary Studies of COVID-19 Beta (B.1.351) Variant Strain Vaccine
|
|
09 Jun 2021 |
INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800
|
|
09 Jun 2021 |
Icosavax Initiates Phase 1/2 Trial of COVID-19 VLP Vaccine Candidate
|
|
09 Jun 2021 |
U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older
|
|
08 Jun 2021 |
HOOKIPA Phase 1 HB-200 data show unprecedented T cell response, favorable tolerability, and preliminary efficacy as monotherapy for advanced HPV16+ cancers
|
|
07 Jun 2021 |
Moderna Files for Conditional Marketing Approval for its COVID-19 Vaccine in Adolescents in the European Union
|
|
07 Jun 2021 |
OliX Pharmaceuticals Subsidiary mCureX Announces Business Agreements to Advance Development of mRNA Vaccines and Therapeutics
|
|
06 Jun 2021 |
Samsung Pharm & GemVax present pancreatic cancer immunotherapeutic drug, RIAVAX™, phase III results at ASCO 2021
|
|
04 Jun 2021 |
Genocea Presents Promising Long-term Results from GEN-009 Neoantigen Vaccine Phase 1 Trial at ASCO 2021
|
|
04 Jun 2021 |
Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program
|
|
04 Jun 2021 |
Geneos Therapeutics Announces Clinical Updates on Personalized Cancer Vaccine Program
|
|
04 Jun 2021 |
Advaccine Announces First Participants Dosed in Phase 2 Study of ADV110 Evaluating Respiratory Syncytial Virus (RSV) Vaccine Candidate in Australia
|
|
02 Jun 2021 |
AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta
|
